Attend any industry conference these days, and a general theme will appear that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage research, could impact long-term future development of emerging biotechnologies. Graeme Martin, president of Takeda's corporate venture arm Takeda Research Investment, talks with PharmAsia News about the changing scope of corporate venture capital in this atmosphere as well as the role of CVC in helping inform companies' development strategies.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
M&A may not be booming in 2025, but BIO convention attendees reported no shortage of potential deals, especially as cash-strapped drug developers seek funding alternatives.
Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
